Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.
Revvity (NYSE: RVTY) ha annunciato una collaborazione ampliata con Genomics England per promuovere iniziative genomic nelle UK. Il partenariato si concentra sul Generation Study, un programma di ricerca che mira a selezionare fino a 100.000 neonati per 200 condizioni genetiche rare in Inghilterra. Attraverso il suo laboratorio Omics a Manchester, Revvity estrarrà DNA da campioni di sangue cordonale utilizzando lo strumento chemagic 360™. La collaborazione mira a migliorare la rilevazione precoce delle condizioni genetiche nei neonati e a sostenere lo sviluppo di talenti genomic nella regione UK.
Revvity (NYSE: RVTY) anunció una colaboración ampliada con Genomics England para avanzar en iniciativas genómicas en el Reino Unido. La asociación se centra en el Generation Study, un programa de investigación que tiene como objetivo examinar hasta 100,000 recién nacidos por 200 condiciones genéticas raras en Inglaterra. A través de su laboratorio Omics en Manchester, Revvity extraerá ADN de muestras de sangre cordonal utilizando el instrumento chemagic 360™. La colaboración tiene como objetivo mejorar la detección temprana de condiciones genéticas en recién nacidos, al mismo tiempo que apoya el desarrollo de talento en genómica en la región del Reino Unido.
Revvity (NYSE: RVTY)는 영국 전역의 유전체 이니셔티브를 발전시키기 위해 Genomics England와의 협력을 확대했다고 발표했습니다. 이 파트너십은 Generation Study에 초점을 맞추고 있으며, 이 연구 프로그램은 잉글랜드에서 100,000명의 신생아를 200개의 희귀 유전 질환에 대해 검사하는 것을 목표로 하고 있습니다. Revvity는 맨체스터에 있는 Omics 실험실을 통해 chemagic 360™ 장비를 사용하여 제대혈 샘플에서 DNA를 추출합니다. 이 협력은 신생아의 유전 질환 조기 발견을 촉진하고 영국 지역의 유전체 인재 개발을 지원하는 것을 목표로 하고 있습니다.
Revvity (NYSE: RVTY) a annoncé une collaboration élargie avec Genomics England pour faire avancer les initiatives génomiques à travers le Royaume-Uni. Le partenariat se concentre sur l'étude Generation Study, un programme de recherche visant à dépister jusqu'à 100 000 nouveau-nés pour 200 maladies génétiques rares en Angleterre. Grâce à son laboratoire Omics à Manchester, Revvity extraira de l'ADN à partir d'échantillons de sang de cordon ombilical en utilisant l'instrument chemagic 360™. La collaboration vise à améliorer la détection précoce des maladies génétiques chez les nouveau-nés tout en soutenant le développement de talents en génomique dans la région du Royaume-Uni.
Revvity (NYSE: RVTY) hat eine erweiterte Zusammenarbeit mit Genomics England angekündigt, um genomische Initiativen im gesamten Vereinigten Königreich voranzubringen. Die Partnerschaft konzentriert sich auf die Generation Study, ein Forschungsprogramm, das darauf abzielt, bis zu 100.000 Neugeborene auf 200 seltene genetische Erkrankungen in England zu筛選. Durch das Omics-Labor in Manchester wird Revvity DNA aus Nabelschnurblutproben mit dem chemagic 360™-Instrument extrahieren. Die Zusammenarbeit zielt darauf ab, die Früherkennung genetischer Erkrankungen bei Neugeborenen zu verbessern und gleichzeitig die Entwicklung von genomanalytischen Talenten in der Region UK zu unterstützen.
- Partnership in major screening program targeting 100,000 newborns
- Expansion of existing relationship with national health organization
- Strategic positioning in UK healthcare market through Manchester laboratory
- None.
Insights
The expanded collaboration between Revvity and Genomics England marks a significant development in newborn genetic screening capabilities in the UK. The Generation Study's ambitious goal to screen 100,000 newborns for 200 rare genetic conditions represents a major advancement in early disease detection and intervention. Revvity's Manchester laboratory will play a important role in DNA extraction using their chemagic 360™ technology, establishing a foundation for comprehensive genetic analysis.
The strategic positioning of operations in Manchester demonstrates a commitment to developing regional expertise in molecular genomics. This geographic expansion could create valuable intellectual property and establish new standards in newborn screening protocols. While the immediate revenue impact may be modest, the long-term potential for developing scalable screening solutions and expanding into other markets is substantial.
A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic conditions in
“We’re grateful for the opportunity to expand our relationship with Genomics England to make a greater impact in saving the lives of babies with this new project,” said Dr. Madhuri Hegde, Revvity’s senior vice president and chief scientific officer. “Additionally, the choice of
Dr. Ellen Thomas, chief medical officer at Genomics England, said, “This partnership is an important contributor to our goal of researching earlier diagnosis and intervention for rare genetic conditions in newborns. By uniting Genomics England’s research expertise with Revvity’s advanced laboratory capabilities, we are proud to reinforce our commitment to advancing genomics research.”
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
About Genomics England
Genomics
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120885442/en/
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Revvity Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com
Genomics England Media:
media@genomicsengland.co.uk
Source: Revvity
FAQ
What is the Generation Study that Revvity (RVTY) is participating in?
How will Revvity (RVTY) contribute to Genomics England's newborn screening program?
What is the scope of Revvity's (RVTY) expanded collaboration with Genomics England?
